Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism

Cancer Letters

Volumn 368, Issue 1, 2015, Pages 88-96

  Ma, Ming Zhe ^a   Chen, Gang ^b   Wang, Peng ^a,c   Lu, Wen Hua ^a   Zhu, Chao Feng ^a   Song, Ming ^a   Yang, Jing ^a   Wen, Shijun ^a   Xu, Rui Hua ^a   Hu, Yumin ^a   Huang, Peng ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemosensitization; Cisplatin; Colorectal cancer; ROS; Sulfasalazine; XCT

Indexed keywords

ACETYLCYSTEINE; CARRIER PROTEIN; CISPLATIN; GLUTATHIONE; PROTEIN XCT; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; ANTINEOPLASTIC AGENT; ANTIOXIDANT; H2AFX PROTEIN, HUMAN; HISTONE; SLC7A11 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COLORECTAL TUMOR; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

AMINO ACID TRANSPORT SYSTEM Y+; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; CELL PROLIFERATION; CISPLATIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HCT116 CELLS; HISTONES; HT29 CELLS; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SULFASALAZINE;

EID: 84940467392     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.07.031     Document Type: Article

References (46)

1. Koizumi W., Narahara H., Hara T., Takagane A., Akiya T., Takagi M., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9:215-221.
2. Vasey P.A., Paul J., Birt A., Junor E.J., Reed N.S., Symonds R.P., et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J. Clin. Oncol 1999, 17:2069-2080.
3. Giacchetti S., Perpoint B., Zidani R., Le Bail N., Faggiuolo R., Focan C., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol 2000, 18:136-147.
4. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol 2006, 24:2137-2150.
5. Gansler T., Ganz P.A., Grant M., Greene F.L., Johnstone P., Mahoney M., et al. Sixty years of CA: a cancer journal for clinicians. CA Cancer J. Clin 2010, 60:345-350.
6. Galluzzi L., Vitale I., Michels J., Brenner C., Szabadkai G., Harel-Bellan A., et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014, 5:e1257.
7. Ramsay E.E., Dilda P.J. Glutathione S-conjugates as prodrugs to target drug-resistant tumors. Front. Pharmacol 2014, 5:181.
8. Stordal B., Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life 2007, 59:696-699.
9. Chen H.H., Kuo M.T. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met.-Based Drugs 2010, 2010.
10. Cui Y., Konig J., Buchholz J.K., Spring H., Leier I., Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol 1999, 55:929-937.
11. Dedoussis G.V., Andrikopoulos N.K. Glutathione depletion restores the susceptibility of cisplatin-resistant chronic myelogenous leukemia cell lines to Natural Killer cell-mediated cell death via necrosis rather than apoptosis. Eur. J. Cell Biol 2001, 80:608-614.
12. Di Pasqua A.J., Hong C., Wu M.Y., McCracken E., Wang X., Mi L., et al. Sensitization of non-small cell lung cancer cells to cisplatin by naturally occurring isothiocyanates. Chem. Res. Toxicol 2010, 23:1307-1309.
13. Wu W.J., Zhang Y., Zeng Z.L., Li X.B., Hu K.S., Luo H.Y., et al. beta-phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype. Biochem. Pharmacol 2013, 85:486-496.
14. Lo M., Wang Y.Z., Gout P.W. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J. Cell. Physiol 2008, 215:593-602.
15. Aquilano K., Baldelli S., Ciriolo M.R. Glutathione: new roles in redox signaling for an old antioxidant. Front. Pharmacol 2014, 5:196.
16. Okuno S., Sato H., Kuriyama-Matsumura K., Tamba M., Wang H., Sohda S., et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br. J. Cancer 2003, 88:951-956.
17. Narang V.S., Pauletti G.M., Gout P.W., Buckley D.J., Buckley A.R. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of doxorubicin. Chemotherapy 2007, 53:210-217.
18. Chung W.J., Lyons S.A., Nelson G.M., Hamza H., Gladson C.L., Gillespie G.Y., et al. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J. Neurosci 2005, 25:7101-7110.
19. Zenlea T., Peppercorn M.A. Immunosuppressive therapies for inflammatory bowel disease. World J. Gastroenterol 2014, 20:3146-3152.
20. Doxsee D.W., Gout P.W., Kurita T., Lo M., Buckley A.R., Wang Y., et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 2007, 67:162-171.
21. Gout P.W., Buckley A.R., Simms C.R., Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 2001, 15:1633-1640.
22. Zhang W., Trachootham D., Liu J., Chen G., Pelicano H., Garcia-Prieto C., et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat. Cell Biol 2012, 14:276-286.
23. Remmele W., Stegner H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8:138-140.
24. Tang Z., Yuan S., Hu Y., Zhang H., Wu W., Zeng Z., et al. Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester. J. Bioenerg. Biomembr 2012, 44:117-125.
25. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180.
26. Takahashi M., Nagai T., Hamano S., Kuwayama M., Okamura N., Okano A. Effect of thiol compounds on in vitro development and intracellular glutathione content of bovine embryos. Biol. Reprod 1993, 49:228-232.
27. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat 2004, 7:97-110.
28. Berndtsson M., Hagg M., Panaretakis T., Havelka A.M., Shoshan M.C., Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int. J. Cancer 2007, 120:175-180.
29. Marullo R., Werner E., Degtyareva N., Moore B., Altavilla G., Ramalingam S.S., et al. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS ONE 2013, 8:e81162.
30. Brozovic A., Ambriovic-Ristov A., Osmak M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit. Rev. Toxicol 2010, 40:347-359.
31. Hu Y., Lu W., Chen G., Zhang H., Jia Y., Wei Y., et al. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate. Blood 2010, 116:2732-2741.
32. Roberts J.J., Pascoe J.M. Cross-linking of complementary strands of DNA in mammalian cells by antitumour platinum compounds. Nature 1972, 235:282-284.
33. Sedletska Y., Giraud-Panis M.J., Malinge J.M. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr. Med. Chem. Anticancer Agents 2005, 5:251-265.
34. Pilch D.R., Sedelnikova O.A., Redon C., Celeste A., Nussenzweig A., Bonner W.M. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem. Cell Biol 2003, 81:123-129.
35. Florea A.M., Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 2011, 3:1351-1371.
36. Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol 2014, 740:364-378.
37. Griffith O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med 1999, 27:922-935.
38. Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci 2006, 43:143-181.
39. Lo M., Ling V., Low C., Wang Y.Z., Gout P.W. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr. Oncol 2010, 17:9-16.
40. Sleire L., Skeie B.S., Netland I.A., Forde H.E., Dodoo E., Selheim F., et al. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc, leading to glutathione depletion. Oncogene 2015, 10.1038/onc.2015.60.
41. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov 2009, 8:579-591.
42. Rosenberg B., Vancamp L., Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 205:698-699.
43. Takeuchi S., Wada K., Nagatani K., Otani N., Osada H., Nawashiro H. Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma. Neurol. India 2014, 62:42-47.
44. Moody G.A., Jayanthi V., Probert C.S., Mac Kay H., Mayberry J.F. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur. J. Gastroenterol. Hepatol 1996, 8:1179-1183.
45. Stolfi C., Pellegrini R., Franze E., Pallone F., Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J. Gastroenterol 2008, 14:4434-4439.
46. Velayos F.S., Terdiman J.P., Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol 2005, 100:1345-1353.